^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BNT113

i
Other names: BNT113, HPV FixVAC, Hare-40 FixVAC, RBLO 15.1(LIP)/RBLO 16.1(LIP), E6/E7 RNA(LIP), HPV mRNA vaccine, HPV anti-CD40 RNA vaccine, BNT 113, BNT-113
Associations
Company:
BioNTech
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Associations
2ms
Observational study on the correlation between the immune response of patients' peripheral blood stimulated by therapeutic HPV mRNA vaccine in vitro and the pathological results and clinical prognosis of patients (ChiCTR2400087487)
P=N/A, N=150, Not yet recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
New trial
|
BNT113
9ms
HARE-40: HPV Anti-CD40 RNA vaccinE (clinicaltrials.gov)
P1/2, N=32, Completed, University of Southampton | Active, not recruiting --> Completed
Trial completion
|
BNT113
11ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • BNT113
2years
Combination therapy • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • BNT113
over3years
Clinical • Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • BNT113
4years
Clinical • New P2 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • BNT113